plantation have been reported [4] . Given the unique susceptibility of cirrhotic patients to cryptococcosis, it is possible that these patients had unrecognized cryptococcal disease before transplantation [5] . Additionally, donor-derived disease has been increasingly recognized as a potential complication of solid-organ transplantation with serious consequences [6] [7] [8] [9] . Whether donor-transmitted cryptococcosis plays a role in cryptococcal disease occurring soon after transplantation has not been well defined.
In this context, we observed that, in our cohort of SOT recipients with cryptococcosis, some patients developed disease within 1 month after transplantation, which was far earlier than the expected onset [10] . Clinical characteristics of cryptococcosis that occurs soon after transplantation are not well-delineated in the literature. Thus, we aimed to characterize very early-onset cryptococcal disease in SOT recipients in our cohort and in the literature and to determine whether it is plausible that unrecognized pretransplant or donor-derived cryptococcosis contributes to this rare event.
MATERIALS AND METHODS
SOT recipients with cryptococcosis were enrolled at participating centers during the period [2003] [2004] [2005] [2006] [2007] [2008] [2009] . Patient management was in accordance with the standard of care at each center. A detailed description of this cohort has been reported elsewhere [10, 11] . None of the patients were human immunodeficiency virus-positive. Cryptococcosis was defined on the basis of criteria proposed by the European Organization for Research and Treatment in Cancer and the Mycoses Study Group [12] . Data collected included demographic characteristics, type of organ transplant, whether antifungal prophylaxis was received within 6 months before diagnosis, whether an immunosuppressive regimen was being administered at the time of diagnosis, whether renal failure was present at baseline (defined as a serum creatinine level 12 mg/dL at the time of diagnosis), whether the patient had experienced rejection of an earlier transplant (within 6 months of diagnosis), whether the patient was receiving retransplantation, whether the patient had cytomegalovirus infection or disease, the site(s) of cryptococcal disease, the type of antifungal therapy employed, and mortality.
For the purpose of this study, very early-onset and late-onset cryptococcosis were defined as disease occurring р30 days and 130 days after transplantation, respectively. Organ sites involved were classified as CNS, pulmonary, skin/soft tissue/osteoarticular; or other sites [1, 10] . Serum or cerebrospinal fluid (CSF) cryptococcal antigen titer у1:512 was considered to represent high fungal load, as reported elsewhere [13, 14] . Disseminated infection was defined as CNS infection or fungemia or involvement of у2 noncontiguous organ sites [1, 10] . Mortality was assessed at 90 days after diagnosis of cryptococcosis.
Additionally, SOT recipients with cryptococcosis reported in the literature were identified by search of the PubMed database through May 2010 with the terms "cryptococcosis" or "Cryptococcus" and "transplantation" or "transplant". Only articles published in English were reviewed. Reference lists of original articles were reviewed for additional cases. Articles were also identified through searches of the authors' own extensive files on these topics [1, 3] . Transplant recipients with disease developing р30 days after transplantation were included in the present study. Statistical analyses. Statistical analyses were performed using Intercooled Stata software, version 9.2 (StataCorp). Categorical data were compared using the x 2 test or Fisher's exact test. Continuous variables were compared using the rank-sum test.
RESULTS
Of 175 SOT recipients with cryptococcosis, 9 (5%) developed the disease р30 days after transplantation. In these 9 patients, cryptococcal disease occurred a mean of 5.7 days after transplantation (interquartile range [IQR], 3-25 days], and 4 of 9 patients developed cryptococcosis within 10 days after transplantation. The demographic and clinical characteristics of patients with very early-onset and late-onset cryptococcosis are presented in Table 1 . In all, 55.6% (5 of 9) of the patients with very early-onset disease versus 25.9% (43 of 166) of those with late-onset disease were liver transplant recipients ( ). On P p .05 the other hand, patients with very early-onset disease were less likely than those with late-onset disease to be kidney transplant recipients (0 [0%] of 9 vs 79 [47.6%] of 166;
). Other P p .005 characteristics of the patients with very early-onset and lateonset of cryptococcosis are outlined in Table 2 . Use of prior antifungal prophylaxis in the study cohort was infrequent (2.2%; 4 of 175 patients). Specifically, none (0 [0%] of 9) of the patients with very early-onset disease and only 2.4% (4 of 166) of the patients with late-onset disease had received prior antifungal prophylaxis ( ). Fungemia was documented P p .63 in 44.4% (4 of 9) of the very early-onset and in 25.7% (38 of 148) of the late-onset cases ( Table 2) . No statistically significant difference between the 2 groups existed with regards to the proportions of patients with disseminated disease, serum or CSF fungal load, and mortality at 90 days ( Table 2) .
In the 9 patients with very early-onset cryptococcosis, the diagnosis was established by culture in 8 (88.9%) and by histopathological findings in 1 (11.1%). Very early-onset cases were more likely to present with cryptococcal disease at sites (other than pulmonary, CNS, or skin) that included the transplanted allograft and surgical fossa/site infections (5 [55.6%] of 9 vs 10 [6.0%] of 166; ) ( Table 2 ). Unrecognized pre-P ! .001 transplant cryptococcosis was suspected in patients 1 and 2 (Table 3) ; these included a liver transplant recipient with Cryptococcus isolated from the lung 1 day after transplantation and a heart transplant recipient with fungemia and positive serum cryptococcal antigen results on day 1 after transplantation. An additional 5 of the 9 very early-onset cases (Table 3 ; patients 3-7) with disease involving the allograft or the surgical sites were likely donor acquired (Table 3) . Patient 3 was a singlelung transplant recipient, and the sole site of involvement 3 days after transplantation was the transplanted lung (Table 3) . Patient 4 was a liver and kidney transplant recipient, and cultures of his peritoneal and perinephric fluids yielded Cryptococcus neoformans. Patient 5 underwent heart transplantation and developed myocarditis and pericarditis after transplantation, with diagnosis established at autopsy. Patients 6 and 7 were both liver transplant recipients with cryptococci in the biliary tract on day 10 and day 21, respectively, one of whom (patient 7) was also fungemic ( Table 3 ). The sources of cryptococcal disease in the remaining 2 of 9 transplant recipients with very early-onset cryptococcosis (ie, a liver transplant recipient with fungemia and CNS and cutaneous disease diagnosed 25 days after transplantation [patient 8] and another liver transplant recipient with pulmonary cryptococcosis that developed 26 days after receipt of the transplant [patient 9]) are less clear (Table 3) . Whether these cases represented very early reactivation or whether the patients had pretransplant cryptococcosis could not be determined. Pretransplant serum samples from these patients were not available for testing for cryptococcal antibodies or antigen.
Very early cryptococcosis in SOT recipients in the literature. In the literature, 9 SOT recipients who developed cryptococcosis р30 days after transplantation were identified and are summarized in Table 4 [15] [16] [17] [18] [19] [20] [21] [22] [23] . Cryptococcosis occurred at a mean of 12.8 days after transplantation (IQR, 7-18 days). Six (66.7%) of the 9 patients were liver transplant recipients, and 4 (57.1%) of the 7 patients with data provided had fungemia. In all, 2 patients received oral nystatin as antifungal prophylaxis at the time of diagnosis, 4 patients did not receive any antifungal prophylaxis, and 3 patients had no data provided. The authors considered unrecognized pretransplant cryptococcosis to be likely in 2 patients, including 1 liver transplant recipient who developed cryptococcal meningitis with cryptococcemia 7 days after transplantation, in whom the pretransplant serum cryptococcal antigen titer was 1:4 [17] . The other case was in a renal transplant recipient with cryptococcal meningitis and cryptococcemia at 14 days after transplantation [15] . Because the disease occurred soon after transplantation, the authors suspected that the patient already had a cryptococcal focus before receiving the transplant.
Donors were proposed to be the source of cryptococcal disease in 2 patients (Table 4) . One patient had received a bilateral a Other sites included peritoneal cavity (1), heart (1), biliary tract (2), and genitourinary tract (1) in the very early group, and genitourinary tract (7), abdominal abscess (1), spinal mass (1), neck mass (1) in the late-onset group; some patients had more than 1 site of involvement.
lung transplant and developed left lobar pneumonia 2 days after transplantation, with fever, leukocytosis, and hypoxemia [18] . C. neoformans was isolated from her respiratory tract cultures. Although the authors considered unusually intense environmental exposure as a possible source of infection, they believed that C. neoformans could have been transmitted from the allograft [18] . The other case occurred in a renal transplant recipient of an allograft from a 20-year-old donor whose untransplanted kidney showed cryptococcal granulomas on biopsy [21] . Cryptococci were isolated from the urine of the recipient 18 days after transplantation and for a few weeks subsequently [21] . Additionally, 1 liver transplant recipient developed disseminated cryptococcosis with involvement of the liver, lung, CNS, and fungemia 10 days after transplantation [19] . The biopsy of the transplanted liver was reported to be negative for C. neoformans.
DISCUSSION
Most post-transplantation cryptococcosis is considered to represent reactivation of latent or quiescent infection in the recipient [24] . Assessment of pretransplant serum samples for cryptococcal-specific antibodies documented that a majority of the SOT recipients with cryptococcosis exhibited serological evidence of infection before transplantation [25] . Although these patients developed cryptococcal disease significantly earlier after transplantation than did those without serological evidence of infection, the median time to onset of disease in patients with prior antibody reactivity and presumed reactivation disease was still 5.6 months [25] . Development of cryptococcosis within 1 month after transplantation is therefore unusual. Our study shows that this entity occurs in 5% of transplant recipients with cryptococcosis and has unique characteristics and disease manifestations. Generally, the degree of immunosuppression is higher in the early post-transplantation period, although no significant differences in disease severity in terms of fungal load and mortality at 90 days were observed between very early-onset and lateonset disease (Table 2) . However, very early-onset cryptococcosis appears to occur preferentially in liver transplant recipients. Indeed, 55.6% and 66.7% of our patients with very earlyonset cryptococcosis and patients with very early-onset cryptococcosis reported in the literature, respectively, were liver transplant recipients (Tables 3 and 4 ). This finding may be related to the susceptibility of liver transplant recipients during transplant candidacy to cryptococcosis. A growing body of evidence suggests that cirrhosis-associated compromised host defenses (such as impaired cell mediated immunity, phagocytic dysfunction, decreased antibody and immunoglobulins, and complement deficiency) is a significant risk factor for cryptococcosis [5] . Furthermore, fungemia occurs in a significant proportion (67%) of patients with cirrhosis-related cryptococcosis [5] , a feature that was also observed in SOT recipients with very early-onset cryptococcosis, both in our cohort and in the literature; 44.4% and 57.1%, respectively, had fungemia (Tables 1, 2 , and 4). Several lines of evidence suggest that, in some cases, very early-onset cryptococcal disease may represent unrecognized pretransplant cryptococcosis. These include documentation of pulmonary disease, fungemia, or cryptococcal antigen positivity as early as day 1 after transplantation in 2 of our patients. Additionally, donor-derived cryptococcosis occurs [18, 21, 26] . CNS, lung, and skin are the most common sites of cryptococcosis in SOT recipients [1] . Indeed 3 of 6 liver transplant recipients in our study had lung disease. However, unusual sites of presentation, such as the transplanted organ as the sole or major site of involvement or isolation of this yeast from surgical sites (abdominal cavity, renal fossa, and biliary tract), suggest that the disease may have been transmitted from the donor. It is also plausible that some cases of cryptococcosis that occur within the first month after transplantation represent early reactivation, particularly after liver transplantation. A state of iron overload in liver transplant recipients that impairs cryptococcal host defenses has been proposed to increase the risk of disseminated disease and may also predispose these patients to early disease after transplantation [27, 28] .
Our study has relevant implications for care providers. Foremost among these is the awareness that cryptococcosis can exist in the recipients before transplantation, even in the absence of iatrogenic immunosuppression, such as the use of corticosteroids. For example, 67% of the patients with end-stage liver disease and cryptococcosis in 1 study had no other underlying predisposing condition [5] . Untreated cryptococcal disease would preclude transplantation; however, indolent pretransplant disease may be unveiled by immunosuppressive therapy with overt disease presenting only after transplantation. Fungemia was documented in 44.4% of our patients with very early disease. Thus, although candidemia occurs more commonly than cryptococcemia in the early post-transplantation period, "yeast isolates" in the blood cultures should be fully identified, given that use of echinocandins is becoming an increasingly common practice for the treatment of fungemia, and these agents have no activity against cryptococci. Finally, surgical site cultures that yield cryptococci should warrant consideration of donor-derived disease. Various types of organ (Tables 3 and 4) and tissue allografts, such as cornea [3] , potentially have the ability to transmit cryptococcosis, and because retrieved organs from a single donor may be used for multiple recipients, prompt notification of organ procurement agencies when donor-derived disease is suspected is crucial.
Several weaknesses of our study deserve to be acknowledged. Because the study was not specifically designed to assess allograft-transmitted disease, detailed information regarding donors was lacking, and retrieval of donor isolates for strain typing was not feasible. However, even in clinical practice, acquisition of donors' medical history is challenging, particularly when they have unexpected or unidentified diseases. Furthermore, depending upon the extent to which the information is accessible, the quality of these data can vary considerably. In addition, pretransplant information for recipients was not available in our cohort to support or refute the argument that, in some cases, cryptococcal disease existed prior to transplantation. Regardless, their pretransplant condition did not offer sufficient clues to physicians to consider the possibility of cryptococcosis and defer transplantation.
In summary, very early-onset post-transplantation cryptococcosis occurs most frequently among liver transplant recipients, often presents with cryptococcemia, and is characterized by involvement of unusual sites, such as the transplanted organ or surgical sites. Some of these patients may have unrecognized pretransplant or donor-derived disease.
